Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Martínez-Marín V, Maki RG · Gastroenterology clinics of North America
Sarcoma subtypes
Abstract
The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review will help the reader understand the present standard of care to improve upon it in years to come.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 27546844. Always confirm details with the original publication or your oncologist.